The safety and efficacy trial of nab-paclitaxel and trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer
Phase 2
- Conditions
- HER2-positive breast cancer
- Registration Number
- JPRN-UMIN000012798
- Lead Sponsor
- Tokyo Medical University Ibaraki Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
1) Pregnant or lactating women 2) Invasive cancer after completion of therapy(less than 5years ) 3) Asynchronous bilateral breast cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pathological complete response rate
- Secondary Outcome Measures
Name Time Method Toxicity Overall survival Relapse free survival